Clinics and research in hepatology and gastroenterology
-
Clin Res Hepatol Gastroenterol · Sep 2013
Correlation between interleukin-6 and ammonia in patients with overt hepatic encephalopathy due to cirrhosis.
Previous studies have shown that elevated serum levels of interleukin-6 (IL-6) correlate with the severity of overt hepatic encephalopathy (OHE) in cirrhotic patients. However, the correlation between serum IL-6 levels and plasma ammonia levels in these patients remains unclear. Therefore, the present study investigated this correlation between both variables in cirrhotic patients with OHE. ⋯ The results of the present study suggest that IL-6 might be involved in the mechanism by which ammonia contributes to the pathogenesis of OHE. There is also evidence of a potential synergistic interaction between proinflammatory cytokines and ammonia in the pathogenesis of OHE.
-
Clin Res Hepatol Gastroenterol · Dec 2012
Case ReportsTreatment of post-liver transplant hepatic artery pseudoaneurysm with balloon angioplasty after failed stent graft placement.
Hepatic artery pseudoaneurysm is a rare complication following liver transplantation but can lead to life threatening hemorrhage if not treated effectively and in a timely manner. We describe a hepatic artery pseudoaneurysm that occurred after liver transplantation in a 53-year-old woman. ⋯ Follow-up ultrasound examinations demonstrated patent hepatic arteries, with no evidence of pseudoaneurysm. Balloon-expandable covered stent-graft may be utilized to treat hepatic artery pseudoaneurysm following liver transplantation, due to the remodeling ability of stent-grafts, enabling them to fit the diseased vessels.
-
Clin Res Hepatol Gastroenterol · Aug 2012
Conceptual framework for classifying the severity of acute pancreatitis.
Acute pancreatitis has been known as a distinct clinical entity since the end of the 19th century, but its management is still characterised by an absence of specific treatments, despite extensive clinical and experimental research. In part this has stemmed from the limitations of the classifications for acute pancreatitis severity used so far. It may well be that the perpetual use of classifications which were solely based on empirical description of severity has retarded progress in the field due to systematic misclassification in selecting patients for clinical trials, evaluating the effects of treatment, and comparing the inter-institutional data. ⋯ These relate to how the classification is best used, what determines the severity of acute pancreatitis, how determinants relate to each other and the time course of determinants. Further, the concept of causal inference is applied to classifying the severity of acute pancreatitis, and the best available evidence suggests that classification of acute pancreatitis severity should be based on local and systemic determinants. It is anticipated that the determinants-based classification of acute pancreatitis severity will underpin the ability of future research to discover a specific treatment for acute pancreatitis and make routine clinical management of patients with acute pancreatitis more tailored and evidence-based.
-
Clin Res Hepatol Gastroenterol · Feb 2012
Case ReportsReactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?
New therapeutic options like monoclonal antibodies (anti-CD20/rituximab) and hematopoietic stem cell transplantation (HSCT) have increased both the effectiveness of therapies and the risk for reactivation of Hepatitis B virus (HBV). We describe two cases with serological evidence of resolved HBV infection (hepatitis B surface antigen (HBsAg) negative/antibody to hepatitis B core antigen (anti-HBc) and antibody to hepatitis B surface antigen (anti-HBs) positive), who developed reverse seroconversion (clearance of HBsAb/appearance of HBsAg) with active HBV infection after treatment with combination of conventional chemotherapy, rituximab and autologous HSCT for hematological malignancies. Review of the literature highlights the increasing incidence of HBV reactivation in patients with resolved infection and raises concerns as to whether current guidelines for pre-chemotherapy screening with sensitive HBV-DNA assays and serial monitoring for anti-HBs titres should be implemented also for patients with resolved infection. Future studies should aim at clarifying the cost-benefit from administration of nucleoside analogues in these patients.